Bergen, Norway 31 January 2022

The overall aim for Lifecare in 2022 is to initiate clinical activities in line
with our development milestones. The planned activities will bring our unique
Sencell osmotic sensing technology a significant step closer to regulatory
approval as a medical device for diabetes care. Preparations to ensure a
regulatory approved platform have been initiated and we are strengthening the
team in Germany at Lifecare NanoBioSensors with supplementary expertise in
nano-microfabrication techniques and project control.    


Read more in the Lifecare January newsletter:
https://lifecare.no/news/information-from-lifecare-january-2022/


This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The Company's patented technology also has the
potential for use in various biomarkers. Lifecare AS is listed on Euronext
Growth (LIFE).

Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no,
+47 40 05 90 40 

This stock exchange announcement was published by Kine Hereid, Investor
Relations at Lifecare AS, on 31.01.22 at 10:10 CET.